Eli Lilly Director Runge Retires

By Tamara Parker • Saturday, August 17 07:53 • Permanent Link

Eli Lilly and Company (NYSE: LLY) has announced the retirement of Marschall S. Runge, M.D., Ph.D., from its board of directors, effective August 31, 2024. Dr. Runge has been a member of Lilly’s board since 2013 and has served on the Science and Technology Committee and Ethics and Compliance Committee.

Dr. Runge, who is currently the CEO of Michigan Medicine, executive vice president for medical affairs at the University of Michigan, and dean of the Medical School, plans to retire on June 30, 2025. Following his retirement from these leadership roles, Dr. Runge will continue to contribute to the Medical School faculty as a professor engaged in providing healthcare and education, as well as pursuing his passion for writing.

During his tenure on Lilly’s board, Dr. Runge has brought decades of experience and expertise in healthcare systems, biomedical research, clinical trial design, and patient safety. His practical experience as a principal investigator has provided a research-driven perspective on diabetes and obesity treatments.

David A. Ricks, Lilly chair and CEO, expressed gratitude for Dr. Runge's valuable service over the last decade, noting that his expertise in science and medical affairs, as well as his patient-centric perspective, have contributed to Lilly’s efforts in bringing medicines to people around the world.

As of the most recent financial reporting period, Lilly's medicines are reported to have helped more than 51 million people globally. The company's scientists are actively advancing new discoveries to address significant health challenges, including redefining diabetes care, treating obesity, advancing the fight against Alzheimer's disease, providing solutions to immune system disorders, and transforming difficult-to-treat cancers into manageable diseases.

Lilly is committed to making life better for millions of people, including by delivering innovative clinical trials that reflect the diversity of the world and working to ensure its medicines are accessible and affordable. To learn more about Lilly, visit Lilly.com and Lilly.com/news, or follow the company on Facebook, Instagram, and LinkedIn. Today the company's shares have moved -1.0% to a price of $922.12. For the full picture, make sure to review Eli Lilly and's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.